Cefotetan Disodium Injection

[19 November 2015]

Products Affected - Description

Cefotetan disodium intravenous powder for solution for injection, BBraun
1 gram/50 mL, Duplex bag, 1 count (NDC 00264-3173-11)
2 gram/50 mL, Duplex bag, 1 count (NDC 00264-3175-11)
Cefotetan disodium intravenous powder for solution for injection, Fresenius Kabi
1 gram vials, 10 count (NDC 63323-0385-10)
2 gram vials, 10 count(NDC 63323-0386-20)
10 gram vials, 1 count (NDC 63323-0396-61)

Reason for the Shortage

  • BBraun has cefotetan on allocation due to current market conditions.
  • Fresenius Kabi states the reason for the shortage is manufacturing delay.

Available Products

There is insufficient supply for usual ordering.

Estimated Resupply Dates

  • BBraun has cefotetan 1 gram and 2 gram Duplex bags on allocation to current customers.
  • Fresenius Kabi has cefotetan 1 gram and 2 gram vials available with short expiration dating (<2 months). The 10 gram vials are on back order and the company estimates a release date of 4th quarter of 2015.


November 19, October 27, September 23, August 11, June 25, May 5, February 2, 2015; November 10, October 1, August 21, July 30, June 3, April 25, 2014, University of Utah, Drug Information Service. Copyright 2015, Drug Information Service, University of Utah, Salt Lake City, UT.


This information is provided through the support of Novation to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Novation, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Novation, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Novation, ASHP nor University of Utah endorses or recommends the use of any drug.

« Back to Drug Shortage Product Bulletins

Advocacy Activity
Get the latest updates on ASHP's advocacy activity on drug shortages.